NOVEL COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES, AUTO-IMMUNE CONDITIONS, LOCAL AND SYSTEMIC INFLAMMATORY DISEASES AND DEGENERATIVE DISORDERS BY LOCAL AND OR SYSTEMIC INJECTIONS OF A MIXTURE OF TRANSGENIC MESENCHYMAL STEM CELLS OR OTHER SOMATIC CELLS EXPRESSING ANTI-INFLAMMATORY CYTOKINES.
Interleukin-4 (IL-4) is a cytokine that blocks the development of contact hypersensitivity. IL-4 also reduces production of TNF-a in interferon- (IFN-) stimulated macrophages and reduces the production of Interleukin IL-1 and prostaglandin E2 (PGE-2). Interleukin - 10 (IL-10) suppresses IFN- production by helper T cells and natural killer cells. IL-10 also reduces secretion of multiple factors originating from the macrophages TNF-a, IL-1a, IL-1, IL-6, granulocyte-macrophage colony stimulatory factor (GM-CSF) and IL-8. Mesenchymal stem cells have immune-modulatory properties and are extremely useful in treating the pathological conditions originating from inflammatory processes. This invention provides the therapeutic benefit of combining the synergistic anti- inflammatory and tissue protective effects of IL-10 and IL-4 along with immune modulation of mesenchymal stem cells.
